Evidence map›Paper›PMID 34820619›Full record

ArticleVaccine: X2021

Long-term immunogenicity and safety of a non-typeable

Philippe De Smedt, Geert Leroux-Roels, Corinne Vandermeulen, Annaelisa Tasciotti, Gennaro Di Maro, Marie Dozot, Daniela Casula, Margherita Annaratone, Daniele Riccucci, Ashwani Kumar Arora

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Immunogenicity and safety of the non-typableHuman vaccines & immunotherapeutics · 2023
    Trial
  3. Review
  4. Development of semisynthetic saponin immunostimulants.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2024
    Review
  5. mBio · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Philippe De SmedtCentre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Geert Leroux-RoelsCentre for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium.
Corinne VandermeulenLeuven University Vaccinology Centre, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
Annaelisa TasciottiGSK, Siena, Italy.
Gennaro Di MaroGSK, Siena, Italy.
Marie DozotGSK, Rixensart, Belgium.
Daniela CasulaGSK, Siena, Italy.
Margherita AnnaratoneGSK, Siena, Italy.
Daniele RiccucciGSK, Siena, Italy.
Ashwani Kumar AroraGSK, Siena, Italy.
Ghent University Hospital · BEGlaxoSmithKline (Belgium) · BEKU Leuven · BEUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A multicomponent vaccine has been developed to reduce the frequency of acute exacerbations of COPD associated with non-typeable

Indexed as

Acute exacerbationAECOPD, acute exacerbations of chronic obstructive pulmonary diseaseANCOVA, analysis of covarianceAntibody persistenceAS01E, Adjuvant System AS01E, containing 3-O-desacyl-4′-monophosphoryl lipid A, QS-21 (Quillaja saponaria Molina, fraction 21) and liposomeCI, confidence intervalClinical trialCOPDCOPD, chronic obstructive pulmonary diseaseELISA, enzyme-linked immunosorbent assayEU, enzyme-linked immunosorbent assay unitsGMC, geometric mean concentrationGMR, geometric mean ratioHaemophilus influenzaeLLOQ, lower limit of quantificationMcat, Moraxella catarrhalisMoraxella catarrhalisMPL, 3-O-desacyl-4′-monophosphoryl lipid ANTHi, non-typeable Haemophilus influenzaePD, protein DPE, protein EPilA, Pilin ApIMD, potential immune-mediated diseaseQS-21, Quillaja saponaria Molina, fraction 21SAE, serious adverse eventUspA2, ubiquitous surface protein A2

Identifiers

PMID34820619
PMCPMC8600057
OpenAlexW3211416232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.